MIM
BRNS

Monashee Investment Management’s Barinthus Biotherapeutics BRNS Stock Holding History

Monashee Investment Management’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-132,184
Closed -$2.22M – 282
2021
Q2 		$2.22M Buy
+132,184
New +$1.96M 0.27% 109

Other funds holding BRNS

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IIM
Ipswich Investment Management Beverly, Massachusetts $474M AUM 35.58% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return
ACA
Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Monashee Investment Management's BRNS Position: Q3 2021 in Review

Monashee Investment Management sold out of Barinthus Biotherapeutics (BRNS) in Q3 2021, closing a stake of 132,184 shares — an estimated $2.22M sold.

Monashee Investment Management first reported a position in BRNS in Q2 2021 and held it in 1 quarter. The position peaked at $2.22M in Q2 2021. 15 funds tracked by Wall St. Rank hold BRNS as of Q3 2021.

  • Monashee Investment Management reported no remaining Barinthus Biotherapeutics position as of Q3 2021 after selling out during the quarter.
  • Monashee Investment Management sold 132,184 Barinthus Biotherapeutics shares in Q3 2021, an estimated $2.22M.
  • Monashee Investment Management first reported a position in Barinthus Biotherapeutics in Q2 2021 and held it in 1 quarter.
  • Monashee Investment Management's Barinthus Biotherapeutics position peaked at $2.22M in Q2 2021.
  • 15 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q3 2021.

Based on Monashee Investment Management's 13F filing for Q3 2021, filed 9 Nov 2021.